Arcutis Biotherapeutics Inc [ARQT] stock prices are down -1.00% to $30.65 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ARQT shares have gain 12.15% over the last week, with a monthly amount glided 21.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on July 25, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 30, 2024, and set its price target to $19. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. Mizuho upgraded its rating to a Buy and increased its price target to $8 on January 03, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $4 on October 26, 2023. Goldman downgraded its rating to Neutral for this stock on October 13, 2023, and downed its price target to $6. In a note dated September 07, 2022, Needham initiated a Buy rating and provided a target price of $46 on this stock.
The stock price of Arcutis Biotherapeutics Inc [ARQT] has been fluctuating between $11.13 and $31.10 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $30.65 at the most recent close of the market. An investor can expect a potential return of 4.4% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
The Arcutis Biotherapeutics Inc [NASDAQ:ARQT] reported sales of 317.93M for trailing twelve months, representing a surge of 121.69%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.3 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.27 points at the first support level, and at 29.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.15, and for the 2nd resistance point, it is at 31.65.
Ratios To Look Out For
It’s worth pointing out that Arcutis Biotherapeutics Inc [NASDAQ:ARQT]’s Current Ratio is 3.50. As well, the Quick Ratio is 3.28, while the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 11.81, the price to book ratio is 23.32.
Transactions by insiders
Recent insider trading involved LIN SUE-JEAN, Director, that happened on Nov 24 ’25 when 25272.0 shares were sold. Watanabe Todd completed a deal on Nov 24 ’25 to sell 48945.0 shares. Meanwhile, Watanabe Todd sold 1055.0 shares on Nov 21 ’25.
